Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability and Efficacy of BST02 in Treating Locally Advanced Liver Cancer

NCT06526832 is registered in ClinicalTrials.gov with BioSyngen Pte Ltd as lead sponsor.

NCT NCT06526832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06526832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability and Efficacy of BST02 in Treating Locally Advanced Liver Cancer
Lead sponsor
BioSyngen Pte Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
July 4, 2024
Completion date
December 3, 2025
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced liver carcinoma